Patients with acute coronary syndromes who require emergency cardiac surgery present complex management challenges. The early administration of antiplatelet and antithrombotic drugs has improved overall survival for patients with acute myocardial infarction, but to achieve maximal benefit, these drugs are given before coronary anatomy is known and before the decision to perform percutaneous coronary interventions or surgical revascularization has been made. A major bleeding event secondary to these drugs is associated with a high rate of death in medically treated patients with acute coronary syndrome possibly because of subsequent withholding of antiplatelet and antithrombotic therapies that otherwise reduce the rate of death, stroke, or recurrent myocardial infarction. Whether the added risk of bleeding and blood transfusion in cardiac surgical patients receiving such potent antiplatelet or antithrombotic therapy before surgery specifically for acute coronary syndromes affects long-term mortality has not been clearly established. For patients who do proceed to surgery, strategies to minimize bleeding include stopping the anticoagulation therapy and considering platelet and/or coagulation factor transfusion and possibly recombinant-activated factor VIIa administration for refractory bleeding. Mechanical hemodynamic support has emerged as an important option for patients with acute coronary syndromes in cardiogenic shock. For these patients, perioperative considerations include maintaining appropriate anticoagulation, ensuring suitable device flow, and periodically verifying correct device placement. Data supporting the use of these devices are derived from small trials that did not address long-term postoperative outcomes. Future directions of research will seek to optimize the balance between reducing myocardial ischemic risk with antiplatelet and antithrombotics versus the higher rate perioperative bleeding by better risk stratifying surgical candidates and by assessing the effectiveness of newer reversible drugs. The effects of mechanical hemodynamic support on long-term patient outcomes need more stringent analysis. (Anesth Analg 2011; 112:777-99) A n early invasive strategy that includes coronary angiography and often percutaneous coronary intervention (PCI) leads to improved survival compared with conservative medical management (e.g., IV thrombolytics) for patients with an acute coronary syndrome (ACS) such as unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), and ST segment elevation myocardial infarction (STEMI). 1 In the United States (US), an estimated 1.3 million PCIs are performed annually (70% with drug-eluting stent placement) underscoring the large public health implications of aggressive coronary artery disease management. 2 Patients may require emergent coronary artery bypass graft (CABG) surgery when the coronary artery disease is not amenable to PCI or when complications develop. Fortunately, the rates of complications from PCIs (e.g., coronary artery dissection or abrupt vessel closure) have markedly decreased since the introduction of intracoronary stents. In a case series from the Mayo Clinic, the incidence of emergency CABG after PCI decreased significantly from 2.9% in the "prestent era" to 0.7% in the "initial stent era" to 0.3% currently (P Ͻ 0.001). 3 Nonetheless, the in-hospital mortality rate for emergency CABG was high and unchanged from 1979 to 2003 (10% to 14%). Caring for patients who require emergency cardiac surgery after PCI is increasingly complex and challenging because of the aggressive use of new antiplatelet and antithrombotic drugs for patients with ACS and the increasing emergency use of mechanical support for hemodynamic stabilization. The purpose of this review is to provide a summary of data from recent large, randomized, controlled trials that have examined the benefit of antiplatelet and antithrombotic drugs on major outcomes for patients with ACS. We focus on therapies recommended for evidence-based treatments of ACS and provide strategies of perioperative management for patients receiving this
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PERIOPERATIVE IMPLICATIONS OF ANTIPLATELET AND ANTITHROMBOTIC AGENTS IN ACS
The pathophysiologic basis of ACS is coronary artery plaque disruption that results in platelet adhesion, thrombus formation, and artery obstruction. Reestablishing coronary flow with thrombolytic therapy or early PCI is the primary treatment for acute myocardial infarction (MI). 4, 5 Therapy with aspirin and unfractionated heparin (UFH) to interfere with ongoing platelet-fibrin formation has been clearly established to reduce death and reinfarction in patients with ACS. 6, 7 Nonetheless, patients with ACS are at persistent short-and long-term risk for recurrent MI and death. This heightened risk may be related in part to the weak antiplatelet effects of aspirin and the limitations of UFH, including its ineffectiveness at inhibiting the enzymatic action of thrombin that is already bound to fibrin clot. 8 Continued thrombin activity not only promotes further fibrin clot formation but also may activate platelets because thrombin is a potent platelet agonist capable of stimulating aggregation even in the presence of aspirin inhibition of thromboxane A2 production. 8, 9 As a result, there has been considerable research to develop more robust antiplatelet drugs and thrombin inhibitors that inactivate both soluble and "clot-bound" fibrin. Extensive data now support the benefits of antiplatelet and antithrombotic agents in the setting of ACS and PCI as reviewed by others. 7,10 -12 Current recommendations for antiplatelet and antithrombotic therapy in ACS and for PCI are summarized in Table 1 .
For patients who require emergency CABG surgery, one must weigh the net benefits of the antiplatelet and antithrombotic drugs against the added risks of perioperative bleeding and blood transfusion that are independently associated with morbidity and mortality. [13] [14] [15] There is no standard definition of major bleeding episodes in clinical trials of antiplatelet and antithrombotic drugs, although definitions evolving from 2 seminal trials of thrombolysis after MI are often quoted. 16, 17 Criteria for major bleeding in nonsurgical patients include intracranial bleeding, cardiac tamponade, or bleeding from any site associated with a Ͼ50 g/dL decrease in hemoglobin. Examples of minor nonsurgical bleeding include bleeding from any site associated with a Ͼ30 g/dL but Ͻ50 g/dL decrease in hemoglobin, hematuria, hemoptysis, hematemesis, or transfusion. Nonetheless, definitions among studies are highly variable and often a composite of all bleeding events or major bleeding unrelated to CABG surgery. Thus, a gastrointestinal bleeding event that is self-limiting after blood transfusion may be counted in the outcome with the same weight as a catastrophic intracerebral bleeding event. Regardless, a major bleeding event is associated with a 5-fold higher risk of death within 30 days in patients with ACS. 18 The reason for the higher risk is not clear, but it may be related to associated hypotension and blood transfusion resulting from bleeding. Alternatively, the link between a major bleeding event and mortality may be attributable to discontinuation of antiplatelet and antithrombotic drugs as a result of bleeding that in turn leads to recurrent myocardial ischemia from withholding of these effective treatments.
Unfortunately, risk factors for bleeding overlap with those for adverse outcome from myocardial reinfarction and, thus, are of little value for individually balancing the risk versus benefit of aggressive antithrombotic therapies. 19 Pocock et al. 20 recently reported an analysis of the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, which involved 13,819 patients with NSTEMI randomized to UFH with a glycoprotein (GP) IIb/IIIa inhibitor, bivalirudin plus a GP IIb/IIIa inhibitor, or bivalirudin alone. These authors reported that 2 risk factors were common for major non-CABG-related bleeding and reinfarction: age and ST segment changes on the admission electrocardiogram (ECG). The impact of the latter ECG changes on mortality was particularly significant early after admission but not 30 days after the event, whereas bleeding complications were associated with mortality throughout the observation and for up to 1 year. Admission ST segment ECG changes might identify patients at high risk for reinfarction who might benefit the most from aggressive antithrombotic therapy. 19 Discontinuing antiplatelet and antithrombotic drugs during the seminal event would predispose this group of patients to risks of recurrent ischemic events. The effect of a bleeding event on long-term outcome was speculated to result from restrictive use of antithrombotic therapy after hospital discharge. Of importance, 37% of the 1647 patients undergoing CABG surgery in the ACUITY trial had a major bleeding episode. 20 The incidence of death within 1 year of treatment was not different for patients with a major bleeding episode after CABG surgery than in those without major bleeding (hazard ratio, 1.01; 95% confidence interval [CI], 0.70 -1.46; P ϭ 0.96). These data might imply that appropriate antiplatelet or antithrombotic therapy should be restarted after CABG surgery once the bleeding episode has been controlled.
Adenosine Diphosphate P2Y 12 Receptor Antagonist
Platelet adenosine diphosphate P2Y 12 receptor activation is an important mechanism of thrombus formation in ACS. Several pivotal trials have established that including a P2Y 12 receptor antagonist in combination with aspirin can help reduce the frequency of death, reinfarction, or stroke in patients with ACS (Table 2) . [21] [22] [23] [24] [25] [26] The thienopyridine clopidogrel has become the primary P2Y 12 receptor antagonist for patients with ACS. A limitation of this agent is that it is a prodrug that requires a 2-step CYP isoenzymedependent activation process in the liver. Polymorphisms in CYP enzymes necessary for converting clopidogrel to its active metabolite are associated with reduced platelet inhibition and worse clinical outcome. 7, [27] [28] [29] Clopidogrel metabolism may also be influenced by other CYP-dependent drugs, such as proton pump inhibitors. 7, 30 The newer thienopyridine, prasugrel, has been suggested to provide more consistent and greater platelet inhibition than clopidogrel. 7, 31, 32 Although also a prodrug, there is no measurable variability in the activating enzymes of prasugrel. A clinical limitation with both clopidogrel and prasugrel is irreversible P2Y 12 receptor blocking effects that are particularly a concern for patients who need CABG For nonprimary PCI: a. If the patient has received fibrinolytic therapy and has been given clopidogrel, clopidogrel should be continued (Level of Evidence: C).
b. If the patient has received fibrinolytic therapy without a thienopyridine, a loading dose of 300-600 mg clopidogrel should be given (Level of Evidence: C).
c. If the patient did not receive fibrinolytic therapy, either a loading dose of 300-600 mg clopidogrel should be given or, once the coronary anatomy is known and PCI is planned, a loading dose of 60 mg prasugrel should be given promptly and no later than 1 h after the PCI (Level of Evidence: B).
For primary PCI in patients receiving aspirin and a thienopyridine, supportive anticoagulant regimens include continued UFH; adjust dose to maintain therapeutic activated clotting time levels, taking into account whether GP IIb/IIIa receptor antagonists have been administered. Bivalirudin is useful for primary PCI with or without prior treatment with UFH. Bivalirudin anticoagulation is reasonable for patients at high risk for bleeding (Level of Evidence: B).
PCI
Patients receiving a drug-eluting stent: clopidogrel 75 mg daily should be given for at least 12 mo.
Patients receiving a bare metal stent: clopidogrel should be given for a minimum of 1 mo and ideally up to 12 mo In patients taking a thienopyridine in whom CABG is planned and can be delayed, it is recommended that the drug be discontinued to allow for dissipation of the antiplatelet effect (Level of Evidence: C). The period of withdrawal should be at least 5 d in patients receiving clopidogrel (Level of Evidence: B) and at least 7 d in patients receiving prasugrel (Level of Evidence: C), unless the need for revascularization and/or the net benefit of the thienopyridine outweighs the potential risks of excess bleeding (Level of Evidence: C).
In STEMI patients with a history of stroke and transient ischemic attack for whom primary PCI is planned, prasugrel is not recommended as part of a dual-antiplatelet therapy regimen (Level of Evidence: C). surgery. Ticagrelor is a new antiplatelet drug that reversibly binds the P2Y 12 receptor. The combination of aspirin with clopidogrel reduces the risk of recurrent ischemic events after PCI with stenting by 3.9% compared with aspirin alone. 33 Recently, it has been highlighted that patients may need the dual antiplatelet therapy for at least 1 year, if not indefinitely, after intracoronary artery insertion of a drug-eluting stent. 34 Analysis of the Duke Cardiovascular Database revealed that for patients with a drug-eluting stent, use of aspirin with clopidogrel was associated with a lower rate (P Ͻ 0.001) of death (0% vs 3.5%) or death and MI (0% vs 4.5%) than was aspirin therapy alone. 35 Use of dual antiplatelet therapy results in conflicting goals for patients who need cardiac surgery. That is, the benefits of these drugs in preserving myocardium and improving survival are balanced against the added risk of perioperative bleeding and transfusion. Preoperative aspirin alone decreases the risk for MI, improves saphenous vein graft patency, and improves survival after CABG surgery, with minimal increased risk for perioperative bleeding and transfusion. 11 Dual therapy with aspirin and clopidogrel, however, has been documented to lead to higher rates of bleeding, blood transfusion, mediastinal reexploration, longer tracheal intubation, and hospitalization for patients who continue therapy within 5 days of CABG surgery. 36 -39 Dual antiplatelet therapy is also associated with a higher risk of infection after CABG surgery-an increase in risk that is independent of baseline comorbidities and perioperative transfusion status. 40 Some reports suggest higher mortality for patients who receive clopidogrel up to the time of CABG surgery, but this is not a consistent finding. 36, 37, 39 The latter data are limited by the fact that they are derived from observational studies. Undergoing CABG surgery within 5 days of receiving clopidogrel may identify a high-risk category of patients who require urgent revascularization.
Current recommendations are to stop clopidogrel for Ն5 days and prasugrel for 7 days before cardiac surgery (Table  1 and Appendix). The needed duration of withdrawal of ticagrelor before cardiac surgery to reduce bleeding risk is not yet known. In vitro studies suggest that platelet function after 3 days of cessation of ticagrelor is similar to that observed after 5 days of withholding clopidogrel. 41 Nonetheless, available data are insufficient to answer the question of whether the reduced risk of bleeding associated with discontinuing clopidogrel before surgery is worth the added risk of myocardial ischemic events. 11 In the Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial, 3491 patients were randomized to receive clopidogrel (300 mg load then 75 mg/d) or placebo in the setting of fibrinolytic therapy and UFH or low-molecular-weight heparin (LMWH) for STEMI. 42 Of this cohort, 136 patients underwent CABG surgery during the initial hospitalization. For patients who stopped the study medication Ͻ5 days before surgery, the rates of major bleeding were 11.4% in the clopidogrel group and 10.5% in the placebo group (absolute risk reduction, 0.9%; CI, 13.5-15.3%; P ϭ 1.0). The 30-day composite end point of cardiovascular death, MI, or repeat revascularization for those undergoing CABG surgery Ͻ5 days after discontinuing medication was 20% in the clopidogrel group and 26.3% in the placebo group (odds ratio [OR], 0.73; 95% CI, 0.23-2.33). In both the CURE and CLARITY-TIMI 28 trials, the majority of improvements in outcomes with clopidogrel were from a reduction in events before cardiac catheterization. 23, 42 For patients undergoing acute cardiac catheterization laboratory intervention, another approach for reducing exposure to antiplatelet therapy might be to withhold therapy until the coronary anatomy is defined and the choice of myocardial revascularization strategy (i.e., PCI versus CABG surgery), if any, is determined. However, this approach ("downstream" administration) might deny patients with ACS the benefit of platelet inhibition during the period of greatest risk. Nonetheless, as many as one-third of intermediate-to high-risk patients with NSTEMI are found to have minimal coronary artery disease at the time of coronary angiography. 43 Administering potent antiplatelet drugs on presentation ("upstream" or before coronary angiography) exposes such patients to unnecessary risk of such therapy. Withholding antiplatelet therapy until after "angiographic triage" does not seem to increase the risk of ischemic complications for patients who eventually undergo PCI after NSTEMI. 43 The reversible binding of ticagrelor to the P2Y 12 receptor may make it clinically useful for patients in whom the coronary anatomy is not known and, thus, for whom the choice of PCI or CABG surgery cannot be immediately determined. In the PLATO study, however, there was no difference in the rates of bleeding or transfusion between patients who received ticagrelor and those who received clopidogrel before undergoing CABG surgery, but the rates of noncardiac surgery bleeding and intracranial hemorrhage were higher in the ticagrelor group (Table 2) . 25 
GP IIb/IIIa Receptor Inhibitors
GP IIb/IIIa receptors are constitutively expressed on the platelet surface and undergo conformational changes after platelet activation to become competent to bind fibrinogen. Interplatelet cross-bridging via fibrinogen leads to platelet aggregation and plug formation. Inhibitors of the GP IIb/IIIa receptor have been shown to benefit subgroups of patients with ACS (Table 3) . 7,44 -51 GP IIb/IIIa inhibitors can be divided into competitive and noncompetitive receptor blocking drugs. Tirofiban and eptifibatide are competitive receptor inhibitors. In contrast, abciximab is a human/murine monoclonal antibody to the GP IIb/IIIa receptor that nearly irreversibly blocks the receptor. Return to 50% GP IIb/IIIa receptor inhibition after abciximab treatment requires nearly 12 hours after stopping the drug. 52 Boersma et al. 53 performed a meta-analysis of 6 randomized trials of GP IIb/IIIa inhibitor treatment in 31,402 patients with ACS who received conservative management. After 30 days, there was a 9% reduction in the odds of death or MI with use of GP IIb/IIIa inhibitors compared with placebo or control therapy (10.8% vs 11.8%; OR, 0.91; 95% CI, 0.84 -0.98; P ϭ 0.015). GP IIb/IIIa inhibitor therapy can result in major bleeding and thrombocytopenia. Improper dosing of GP IIb/IIIa inhibitors was implicated as a contributing factor in bleeding in a retrospective analysis. 11 In that study, older age, female sex, renal insufficiency, low body weight, diabetes, and congestive heart failure were associated with GP IIb/IIIa dosing outside of guidelines. A recent analysis of data from the National Cardiovascular Data Registry involving 829 US hospitals and 22,778 patients found that contraindicated medications were used in 22.3% of patients on dialysis who were undergoing PCI. 54 The risk of major bleeding was linked to improper medication administration. Analysis of data from the other multicenter data showed no difference in transfusion rates and major bleeding in patients undergoing surgery after receiving abciximab compared with placebo. 55 These data do not apply to emergency CABG surgery, because many patients stopped abciximab Ͼ12 hours before surgery. Others reported high rates of bleeding and transfusion when abciximab was given Ͻ12 hours after CABG surgery. 56 Tirofiban and eptifibatide each have a shorter half-life than abciximab (approximately 2 hours), a feature that allows for more rapid dissipation of their antiplatelet effects and decreases the risk of bleeding in patients who require urgent or emergent CABG surgery. 57, 58 These drugs should be discontinued 4 hours before surgery to reduce the risk of bleeding (Appendix).
Low-Molecular-Weight Heparin
LMWHs are Յ5000-Da fragments of UFH that have better bioavailability than UFH and produce less platelet activation and sensitization. 7 Similar to UFH, LMWH acts via antithrombin to inhibit thrombin, but it also inhibits activated factor X. The latter effect is greater with shorter fragment length.
Monitoring the effectiveness of anticoagulation with LMWH is problematic because the partial thromboplastin time is insensitive to therapeutic doses of LMWH. Measuring antifactor Xa activity is one approach that is increasingly considered. Importantly, LMWHs are excreted by the kidneys, necessitating dose adjustment in the presence of renal impairment. 7, 59 Only 60% of the anticoagulant effect of LMWH can be reversed with protamine. 7 In the presence of bleeding, it has been suggested that 1 mg of protamine be given for each 100 antifactor Xa units if LMWH was given within 8 hours. 60 One frequently used LMWH is enoxaparin. Compared with UFH, enoxaparin treatment, when added to aspirin with or without a GP IIb/IIIa receptor inhibitor, has been shown to be beneficial for low-risk patients with unstable angina or NSTEMI managed medically. [61] [62] [63] However, in some trials, higher rates of bleeding were observed with enoxaparin than with UFH. 64 The use of LMWH as a procedural anticoagulant for PCI did not lead to higher rates of bleeding complications compared with UFH. 65, 66 In one of the analyses, 67 the primary outcome of non-CABG-related major bleeding at 48 hours was lower in patients receiving 0.5 mg/kg enoxaparin than in those receiving UFH (5.9% vs 8.5%; P ϭ 0.01) but not in those receiving 0.75 mg/kg enoxaparin (6.5%; P ϭ 0.051).
A meta-analysis of 6 randomized trials that compared enoxaparin and UFH in 21,946 patients with NSTEMI found no difference in the incidence of death at 30 days after treatment (3.0% vs 3.0%; OR, 1.00; 95% CI, 0.85-1.17). 68 A reduction in the occurrence of the combined end point of death or nonfatal MI at 30 days was noted for patients receiving enoxaparin compared with UFH (10.1% vs 11.0%; OR, 0.91; 95% CI, 0.83-0.99). Overall, there was no difference in the rate of blood transfusion (OR, 1.01; 95% CI, 0.89 -1.14) or major bleeding (OR, 1.04; 95% CI, 0.83-1.30). Enoxaparin has been evaluated in high-risk patients with ACS managed with an early invasive strategy (Table 4) . 7,10,64,69 -71 The relationship between enoxaparin and CABG-related bleeding events depends on the timing of surgery after cessation of antithrombotic therapy. 15 In the SYNERGY trial, 18.1% of 9053 patients eventually underwent CABG surgery. 72 Of those undergoing CABG surgery, nearly 50% did so within 72 hours of angiography. Patients who received early CABG surgery had more bleeding events (39.2% vs 29.4%; P Ͻ 0.001) but not death or MI compared with patients who did not undergo the surgery. The risk of bleeding was reduced when surgery was delayed Ͼ18 hours after stopping enoxaparin and GP IIb/IIIa receptor inhibitors. It is recommended that enoxaparin be discontinued 12 to 24 hours before cardiac surgery to decrease the risk of bleeding (Appendix).
Direct Thrombin Inhibitors
Direct thrombin inhibitors (DTIs) block thrombin's ability to convert fibrinogen to fibrin, and to activate coagulation factors XI, X, and XII, as well as platelets. 7 Of the available DTIs, bivalirudin is the only drug recommended for patients with ACS (Table 1) . Bivalirudin is a 20 -amino acid synthetic peptide that has a biphasic effect on thrombin. Initially, bivalirudin is a noncompetitive inhibitor of thrombin, but it is slowly cleaved by thrombin, allowing for some eventual functional recovery. 7 The half-life of bivalirudin is 25 minutes and determined by proteolysis and renal clearance.
A meta-analysis of 11 randomized trials involving 35,970 patients with ACS found that patients who had received at least 7 days of DTI therapy had a lower risk of death or MI after 30 days than patients who had received UFH (7.4% vs 8.2%; OR, 0.91; 95% CI, 0.84 -0.99; P ϭ 0.02). 73 This result stemmed mostly from a reduction in the rate of MI that occurred in 2.8% of DTI-treated patients and 3.5% of UFH-treated patients (P Ͻ 0⅐001). Studies in which bivalirudin was evaluated in patients with ACS undergoing PCI have reported lower rates of death with DTIs than with UFH (Table 5 ). 74 -79 Interpretation of the results of many of the trials has been debated with respect to the adequacy of anticoagulation in the control patients, end point definitions, and study patient populations. 7 The lack of a specific antidote for DTIs may complicate perioperative management of patients requiring emergency cardiac surgery. Nonetheless, the short half-life of bivalirudin may allow for clearance of the drug in all patients except for those with renal dysfunction. Interestingly, a pooled analysis of 3 randomized trials in which 35 of 12,921 patients had coronary artery perforation during PCI revealed that patients treated with bivalirudin had outcomes similar to those treated with UFH and a GP IIb/IIIa receptor inhibitor. 80 The feasibility of anticoagulation with bivalirudin during cardiac surgery with or without cardiopulmonary bypass (CPB) has been demonstrated including in patients with heparin-induced thrombocytopenia. [81] [82] [83] [84] Although not significant, there was a trend for higher rates of bleeding end points including chest reexploration for patients receiving bivalirudin compared with UFH. These studies, however, were not powered to adequately assess the safety of bivalirudin for anticoagulation during cardiac surgery. It is recommended that bivalirudin be discontinued Ն3 hours before cardiac surgery to reduce the risk of bleeding (Appendix). 
Factor Xa Inhibitors
Fondaparinux is a synthetic pentasaccharide that activates antithrombin III by inducing a conformational change in the enzyme. The activated antithrombin III then irreversibly inhibits factor Xa. 85 It is administered subcutaneously with once-a-day dosing. Prospectively randomized, double-blind trials have shown that, compared with enoxaparin, fondaparinux reduces the incidence of venous thromboembolism after major orthopedic surgery, without a difference in bleeding events. 85 The OASIS-5 86 and OASIS-6 87 trials evaluated the use of fondaparinux in patients with NSTEMI and STEMI, respectively (Table 6 ). Major bleeding was lower with fondaparinux than with enoxaparin in OASIS-5 but not versus usual care in the OASIS-6 trial. Notably, patients with major bleeding in the former study had higher mortality (13.2% vs 2.8%), reinfarction (11.9% vs 3.6%), or stroke (3.5% vs 0.7%) 30 days after randomization (P Ͻ 0.001) compared with those without major bleeding regardless of treatment group. The observed decrease in mortality with fondaparinux compared with enoxaparin resulted from its ability to reduce major bleeding. Rates of mortality, MI, and recurrent ischemia were similar for patients receiving fondaparinux and enoxaparin who underwent PCI. Higher rates of thrombus formation were observed on the PCI catheters in the fondaparinux group, an effect that could be avoided by coadministration of UFH. Fondaparinux should be stopped 24 hours before cardiac surgery to decrease the risk of bleeding (see Appendix).
MANAGEMENT OF PERIOPERATIVE BLEEDING
There are no specific evidence-based guidelines for managing bleeding due to coagulopathy in the cardiac surgical patient who has received antiplatelet or antithrombotic drugs for ACS. 88 Suggested management for such patients is listed in Table 7 . As a general principle, patients who require emergent cardiac surgery and are receiving antiplatelet or antithrombotic drugs should first discontinue the drug. Performing CABG surgery without CPB is one consideration if the patient is a suitable candidate. If CPB is planned, the dose of heparin should not be reduced in the presence of such drugs, because incomplete inhibition of thrombin may lead to secondary platelet activation and consumption. 88 Platelet transfusion is typically the first line of therapy for bleeding in patients receiving antiplatelet therapy before surgery. In fact, some evidence suggests that clopidogrel's antiplatelet effects can be reversed with platelet transfusions. 89, 90 Nonetheless, platelets should not be transfused prophylactically. Several pharmacologic strategies have been proposed for managing patients who are receiving antiplatelet drugs before cardiac surgery, including antifibrinolytic therapy and desmopressin. 88 Plasma-derived and synthetic coagulation factor concentrates such as fibrinogen, factor XIII, and recombinant-activated factor VIIa (rFVIIa) have been used in patients with excessive perioperative bleeding. 88, 91 Because these components are either pasteurized or synthesized by recombinant DNA technology, there is There was no difference in the incidence of TIMI major bleeding episodes in patients receiving fondaparinux versus usual care (P ϭ 0.13).
Note that specific definitions of bleeding for each analysis are summarized in the relevant column whereas definitions arising from the Thrombolysis in Myocardial Infarction (TIMI) trial 16 and the Global Utilization of Streptokinase and t-PA for Occluded coronary arteries (GUSTO) trial 17 are summarized in the footnote below. CI ϭ confidence interval; GP ϭ glycoprotein; HR ϭ hazard ratio; MI ϭ myocardial infarction; PCI ϭ percutaneous coronary intervention; STEMI ϭ ST elevation myocardial infarction; UFH ϭ unfractionated heparin; ACS ϭ acute coronary syndrome. TIMI major bleeding ϭ intracranial bleeding; overt bleeding with a decrease in hemoglobin Ͼ5 g/dL or a decrease in hematocrit Ͼ15%. TIMI minor bleeding ϭ spontaneous gross hematuria; spontaneous hematemesis; observed bleeding with decrease in hemoglobin Ͼ3 g/dL but Ͻ15%. GUSTO major bleeding ϭ deadly bleeding; intracerebral bleeding; substantial hemodynamic compromise requiring treatment. GUSTO moderate bleeding ϭ bleeding requiring transfusion. GUSTO minor bleeding ϭ other bleeding not requiring transfusion or causing hemodynamic compromise.
a reduced risk of infectious-agent transmission compared with allogeneic blood transfusion. rFVIIa is specifically indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to factor VIII or factor IX or for the treatment of bleeding episodes and the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia. 92 Although not entirely elucidated, the mechanism of the hemostatic effects of rVIIa seems to be local generation of thrombin at the site of vessel injury. 93 The US Food and Drug Administration has recently added a "black box" warning to prescribing information for the coagulation factor VIIa drug NovoSeven (Novo Nordisk, Inc., Princeton, NJ) because of possible serious thrombotic adverse events when the product is used outside of labeled indications. 94 Procoagulant proteins are normally localized to the site of vascular injury by endothelial-based and systemic antithrombotic and fibrinolytic processes as previously reviewed. 88, 91 As a result, few activated coagulation proteins escape the site of endothelial disruption, and those that do are rapidly inactivated by antithrombotic factors such as antithrombin III and tissue factor pathway inhibitor. The fine balance between prothrombotic and antithrombotic processes can be disrupted perioperatively. For example, patients may have a deficiency of antithrombotic proteins or have prothrombotic conditions induced by surgical trauma/inflammation and blood coagulation factor administration. Of particular concern is that administration of rFVIIa in excess of that needed to stop microvascular bleeding may overwhelm antithrombotic processes and lead to systemic thrombus formation and organ injury.
Mortality and complication rates of patients who receive rFVIIa for uncontrolled bleeding after cardiac surgery have been reported to range from 19% to 40%, but these studies lacked a control group for comparison. [95] [96] [97] [98] [99] The rates of serious adverse events in 51 patients receiving rFVIIa for life-threatening bleeding after cardiac surgery were not higher than those of propensity-matched controls. 100 In a multicenter study, Gill et al. 95 randomized patients with life-threatening bleeding after cardiac surgery to receive in a double-blind design placebo (n ϭ 68), 40 g/kg rFVIIa (n ϭ 35), or 80 g/kg rFVIIa (n ϭ 69). Compared with the placebo group, fewer patients receiving rFVIIa underwent reoperation for bleeding (P ϭ 0.03) or required allogeneic transfusions (P ϭ 0.01). There were more serious adverse events in patients receiving rFVIIa than in those receiving placebo (placebo, 7%; 40 g/kg rFVIIa, 14%, P ϭ 0.25; 80 g/kg rFVIIa,12%, P ϭ 0.43). The odds ratio (95% CI) for a serious adverse event in patients receiving 40 g/kg rFVIIa, 80 g/kg FVIIa, and both rFVIIs combined was 2.16 (0.58 -8.12), 1.61 (0.50 -5.25), and 1.67 (0.50 -5.47), respectively. Nonetheless, this study was underpowered to accurately assess the risk for serious adverse events from rFVIIa administration. Furthermore, patients receiving rFVIIa were older, had longer duration of CPB, and received more transfusions before randomization. Thus, before using rFVIIa in patients with life-threatening bleeding after cardiac surgery, one must balance the potential benefits of avoiding events associated with poor outcome (e.g., massive blood transfusion, mediastinal reexploration for bleeding) against the unknown safety of the compound.
ACUTE MECHANICAL CIRCULATORY SUPPORT
Several mechanical options are available to support the circulation of patients with cardiogenic shock, including an intraaortic balloon pump (IABP), percutaneous extracorporeal membrane oxygenation (ECMO), and left ventricular assist devices (LVADs). Insertion of an IABP in patients with acute MI and cardiogenic shock may decrease mortality, particularly when early myocardial revascularization is performed. [101] [102] [103] Although it decreases left ventricular preload and afterload, an IABP might not preserve left ventricular myocardial mass. 104, 105 Circulatory Support with ECMO
The clinical use of ECMO was first described for treating patients with acute respiratory distress syndrome. 106, 107 Initially, use of this application with the then frequently used CPB film or bubble oxygenators was limited by problems such as hemolysis and platelet consumption. 108 These limitations were somewhat overcome with the introduction of the silicone membrane oxygenator. 109 Gas transfer with the latter is across a solid, flat woven membrane that is sealed at the edges to allow blood to flow over an envelope containing gases. These membranes are suitable for long-term use because they have high biocompatibility. However, silicone membranes have rather inefficient gas exchange and so require a large surface area, large priming volume, long duration for priming, a high pressure gradient, and high resistance to flow. 109 These limitations led to the development of hollow-fiber polypropylene microporous oxygenators that have a more efficient gas exchange, have a smaller surface area, require less priming volume, and require a lower pressure gradient. Leakage of plasma proteins across the microporous membrane diminishes oxygen transport, limiting the duration of use of these oxygenators to less than 6 to 8 hours. 110 More recently, polymethylpentene oxygenators have been introduced for ECMO that overcome plasma leakage associated with polypropylene oxygenators. 111 These oxygenators are microporous sheets rather than hollow fibers, are easy to prime, have high gas exchange efficiency, and high biocompatibility similar to that seen with silicone oxygenators. Early experience with polymethylpentene oxygenators supports their suitability for long-term ECMO support. 112, 113 The exact device used for ECMO depends on shortnotice availability. Simplified cardiopulmonary support (CPS) system ECMO devices are often kept assembled but not primed for rapid deployment. These devices include a centrifugal pump and are composed of a microporous hollow polypropylene fiber oxygenator similar to those used during CPB.
The clinical use of bedside ECMO has been most thoroughly evaluated for patients with pulmonary failure. 108 There are no data from randomized trials that have evaluated the use of ECMO for management of patients with cardiogenic shock. A meta-analysis of 11 clinical series and 9 case reports involving 135 adult patients receiving ECMO after cardiac arrest, however, revealed survival to hospital discharge in 56% of patients 17 to 40 years old compared with 9% survival in patients Ͼ67 years. 114 In another series of 975 patients, survival to discharge, 30-day survival, and 1-year survival were higher for patients who received ECMO (n ϭ 59) after 10 minutes of cardiopulmonary resuscitation (CPR) than for propensity-matched controls who received only CPR (n ϭ 113). 115 Using data gathered from 116 member centers of the Extracorporeal Life Support Organization Registry, Thiagarajan et al. 116 reported that of 295 adult patients who underwent ECMO after cardiac arrest, 27% survived to hospital discharge. In contrast, a survey of outcomes from 14,720 cardiac arrests showed survival after in-hospital CPR to be 17%. 117 Factors associated with survival after ECMOsupported CPR based on multivariate logistic regression analysis were acute myocarditis (OR, 0.18; 95% CI, 0.05-0.69) and use of percutaneous cannulation techniques (OR, 0.42; 95% CI, 0.21-0.87).
Circulatory Support with Percutaneous LVADs
Insertion of an LVAD in patients with cardiogenic shock restores systemic perfusion and reduces systemic inflammation that accompanies and aggravates poor left ventricular function. 102, 118 Several case series have shown improved in-hospital survival with an aggressive strategy that includes LVAD insertion with early revascularization. 102, 118 LVADs can be inserted either surgically or percutaneously. Experience with the former is widespread in most busy cardiac surgical centers, but the percutaneous LVAD (pLVAD) is increasingly being used and offers the advantage of prompt insertion and early restoration of hemodynamics and organ perfusion.
Three pLVADs are approved for use in the US: the TandemHeart (Cardiac Assist, Inc., Pittsburgh, PA; Fig.  1 ) and the Impella LP 2.5 and Impella LP 5.0 (Abiomed, Danvers, MA; Fig. 2 ). The TandemHeart device provides circulatory support through a 21F venous cannula inserted transseptally into the left atrium. It returns oxygenated blood via the femoral artery by using a centrifugal pump 102, 119 and provides a flow of 4.0 L/min. The Impella Recover LP 2.5 system is an axial rotary pump mounted on a catheter with 4.0-mm external diameter that is placed across the aortic valve via a retrograde arterial approach. 102 The pump outlet and motor are positioned in the aorta. The Impella LP 5.0 pump has a diameter of 7.3 mm at its outflow and a diameter of 6.3 mm for the portion positioned in the heart. The Impella pump is controlled by a microelectric motor at a maximal flow of 2.5 L/min for the LP 2.5 and 5.0 L/min for the LP 5.0 device.
Preliminary use of the TandemHeart has been reported in a small, single-center case series. 119 -122 In a retrospective analysis of data from 18 patients who developed cardiogenic shock after MI, the TandemHeart was used for an average of 4 Ϯ 3 days and achieved a mean flow of 3.2 Ϯ 0.6 L/min. Cardiac index improved from 1.7 Ϯ 0.3 L/min/m 2 before pLVAD insertion to 2.4 Ϯ 0.6 L/min/m 2 after insertion (P Ͻ 0.001). The 30-day mortality rate was 44%. 119 Limb ischemia was reported in 15% of patients. 102 In a multicenter study, patients with cardiogenic shock from MI or cardiac heart failure were randomized to treatment with an IABP (n ϭ 14) or the TandemHeart (n ϭ 19). 123 The mean duration of support was 2.5 days. Compared with patients with an IABP, those receiving the TandemHeart had a higher cardiac index and mean arterial blood pressure, and lower pulmonary capillary wedge pressure. Thiele et al. 124 randomized patients who were undergoing PCI because of post-MI cardiogenic shock to either IABP (n ϭ 20) or pLVAD support with the TandemHeart (n ϭ 21). The primary outcome measure, cardiac power index, was improved by pLVAD support from 0.22 W/m 2 (interquartile [IQ] range, 0.19 -0.30) to 0.37 W/m 2 (IQ range, 0.30 -0.47; P Ͻ 0.001). In the IABP group, cardiac power index increased from 0.22 W/m 2 (IQ range, 0.18 -0.30) to 0.28 W/m 2 (IQ range, 0.24 -0.36; P ϭ 0.02 but P ϭ 0.004 compared with pLVAD). Severe bleeding (n ϭ 19 vs n ϭ 8; P ϭ 0.002) and limb ischemia (n ϭ 7 vs n ϭ 0; P ϭ 0.009) were more common in the pLVAD group, but 30-day mortality was similar (IABP 45% vs pLVAD 43%; log-rank, P ϭ 0.86). The mean duration of support was 2.5 days.
The feasibility of the Impella Recover LP 2.5 system was examined in a series of 19 high-risk patients undergoing PCI. 125 Maximal support was for 120 minutes, and the device was removed after the procedure. The Impella LP 5.0 has been used in patients with ventricular failure after cardiac surgery, after MI, and in patients with cardiomyopathy or myocarditis. 126 -128 Seyfarth et al. 115 prospectively randomized 26 patients with cardiogenic shock to receive either an IABP (n ϭ 13) or Impella Recover LP 2.5 pLVAD (n ϭ 12). Cardiac index after 30 minutes of support was increased in patients with the Impella LP 2.5 compared with patients who received the IABP (increase of 0.49 Ϯ 0.46 vs 0.11 Ϯ 0.31 L/min/m 2 ; P ϭ 0.02). Overall 30-day mortality was 46% in both groups. Although these studies show the feasibility of using both pLVAD systems, the small sample size precludes an assessment of safety and efficacy.
The general indications for pLVAD placement include (1) providing temporary support of severe, reversible left ventricular failure until revascularization or recovery, (2) providing temporary support for high-risk PCI when there is a large area of at-risk myocardium, and (3) bridging support to a permanent LVAD or heart transplantation. 129 Relative contraindications are severe right ventricular failure, severe peripheral vascular disease, and coagulopathy.
Perioperative Considerations
Arterial and venous cannulation for ECMO can be percutaneous or via a cut-down such as of the femoral vessels. Anticoagulation for ECMO by a silicone oxygenator is usually targeted to an activated clotting time in the range of 200 seconds. Complications of ECMO include air embolism, coagulation and platelet consumption leading to bleeding and blood transfusion, stroke, infection, and multiorgan failure leading to death. 108 In contrast, ECMO that is performed via a CPS system that uses a CPB-type oxygenator requires full anticoagulation. For pLVADs, the goal of anticoagulation is an activated clotting time Ͼ250 seconds during device insertion and Ͼ200 seconds during support. Physical examination and checking the pulse by palpation or with Doppler methods is required at least hourly.
Clinical management of patients receiving ECMO has been previously reviewed. 108 Blood flow with ECMO and CPS is set to achieve normotension, normal pH, and satisfactory oxygen saturation. This is typically achieved with a pump flow of 50 to 80 mL/kg/min and a sweep gas flow of 50 to 80 mL/kg/min at a fraction of inspired oxygen of 1.0. When venous-arterial ECMO is used, lung ventilation can be minimized to limit peak inspiratory pressure to Ͻ25 cm H 2 O.
Special perioperative considerations with the Tan-demHeart include monitoring of the left atrial cannula with transesophageal echocardiography (Fig. 3) . Displacement of the cannula into the right atrium results in a right-to-left shunt and systemic perfusion with deoxygenated blood. An assessment of the abdominal aorta and iliac and femoral arteries should be considered to exclude arterial atherosclerosis or stenosis before placement of the Impella device. Echocardiography should be used to exclude left ventricular thrombus and to examine the aortic valve for abnormalities and aortic valve regurgitation. Monitoring the position of the Impella device with transesophageal echocardiography is necessary to ensure correct positioning and to monitor for aortic regurgitation (Fig. 4) . Because of the high-speed rotary pump, hemolysis can occur with the Impella Recover LP 2.5 or 5.0, usually within the first 24 hours. Weaning can be considered when the cardiac index is Ͼ2.0 L/min/m 2 , the mean arterial blood pressure is Ͼ70 mm Hg, there is minimal inotropic support, and there is no evidence of end-organ hypoperfusion.
CONCLUSIONS
The aggressive use of antiplatelet and antithrombotic drugs has improved outcomes in patients presenting with NSTEMI or STEMI. However, for those patients who proceed to emergency cardiac surgery, mortality has remained high, and perioperative management is complex. To achieve maximal benefit, antiplatelet and antithrombotic drugs are given before coronary anatomy is known and before the risk of proceeding to surgery has been defined. For patients who do proceed to surgery, strategies to minimize bleeding include stopping the anticoagulation therapy and considering platelet/ coagulation factor transfusion or rFVIIa administration for refractory bleeding. Mechanical hemodynamic support has emerged as an important option for patients in cardiogenic shock who proceed to surgery. For these patients, perioperative considerations include maintaining appropriate anticoagulation, ensuring appropriate device flow, and periodically verifying correct device placement. Future directions of research will include optimizing the balance between reducing myocardial ischemic risk with antiplatelet and antithrombotics versus the higher rate perioperative bleeding by better risk stratifying of surgical candidates and by assessing the effectiveness of newer reversible drugs. The effect of mechanical hemodynamic support on long-term patient outcomes needs more stringent analysis. 
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APPENDIX: SUMMARY OF CLINICAL IMPLICATIONS OF RECOMMENDED ANTIPLATELET AND ANTITHROMBOTIC DRUGS FOR ACUTE CORONARY ARTERY SYNDROMES

Antiplatelet Drugs
Drug: Aspirin Mechanism of action:
• Irreversibly inhibits cyclooxygenase-1 interrupting platelet activation via prostaglandin pathway Perioperative considerations:
• Preoperative aspirin lowers the risk for MI, improves saphenous vein graft patency, and improves survival after CABG surgery. Recommendations for drug withdrawal before cardiac surgery:
• There is minimal increased risk for perioperative bleeding and transfusion when aspirin is continued until the time of surgery.
Drugs: clopidogrel, prasugrel, and ticagrelor Mechanism of action:
• Inhibition of platelet adenosine diphosphate P2Y 12 receptor activation. • Clopidogrel is a prodrug that requires a 2-step liver CYP isoenzyme-dependent activation.
• Polymorphisms involving CYP enzymes and CYP inhibitors such as proton pump inhibitors may reduce platelet inhibition. • Clopidogrel is characterized by slow onset and variable effect with inadequate clinical response in 15% to 30% of patients.
• Clopidogrel 75 mg and 600 mg requires 5 days and 8 hours, respectively, for 50% platelet inhibition.
• Prasugrel provides more consistent and greater platelet inhibition than clopidogrel. [1] [2] [3] Prasugrel is a prodrug, but there is no measurable variability in the activating enzymes.
• Clopidogrel and prasugrel are irreversible P2Y 12 receptor blockers.
• Ticagrelor is a reversible P2Y 12 receptor blocker.
Perioperative considerations:
• Dual therapy with aspirin and clopidogrel is associated with higher rates of bleeding, blood transfusion, mediastinal reexploration, longer tracheal intubation, and hospitalization for patients who continue therapy within 5 days of coronary artery bypass graft (CABG) surgery.
• Clopidogrel may also be associated with a higher risk of infection after CABG surgery.
• Bleeding risk is higher with prasugrel than with clopidogrel.
• Whether ticagrelor lowers the risk of perioperative bleeding compared with clopidogrel or prasugrel for patients undergoing CABG surgery is not yet established.
Recommendations for drug withdrawal before cardiac surgery:
• Clopidogrel should be stopped 5 to 7 days before surgery. • Prasugrel should be stopped at least 7 days before surgery.
• Duration for withdrawal of ticagrelor is not yet established. In vitro studies suggest that ticagrelor should be stopped 72 hours before surgery.
Drugs: abciximab, tirofiban, and eptifibatide
Mechanism of action:
• Glycoprotein (GP) IIb/IIIa receptor inhibition blocking fibrinogen binding and platelet aggregation. • Tirofiban and eptifibatide are competitive receptor inhibitors.
• Abciximab is a human/murine monoclonal antibody to the GP IIb/IIIa receptor that nearly irreversibly blocks the receptor.
Perioperative considerations:
• Return to 50% GP IIb/IIIa receptor inhibition after abciximab treatment requires nearly 12 hours after stopping the drug.
• Therapy with any agent can result in major bleeding and thrombocytopenia.
• Tirofiban and eptifibatide have a half-life of approximately 2 hours.
• Discontinue tirofiban or eptifibatide 4 hours before surgery.
Antithrombotic Drugs
Drug: unfractionated heparin. Mechanism of action:
• Bovine and porcine sources.
• Indirectly inhibits thrombin by first binding to antithrombin.
Perioperative considerations:
• Clinical use easily monitored with partial thromboplastin time and activated clotting time. • Reversal with protamine.
• Prolonged infusion can result in reduction in antithrombin activity.
• Heparin-induced thrombocytopenia with/without thrombosis.
• Does not effectively block thrombin that is bound to thrombus ("clot bound thrombin").
• Varies among institutions, but infusions are frequently continued until the time of surgery.
Drug: Enoxaparin. Mechanism of action:
• Low-molecular-weight heparins (LMWHs) are Յ5000-Da fragments of unfractionated heparin. • Require antithrombin to inhibit thrombin.
• Inhibits activated factor X and thrombin (antifactor Xa/IIa ratio ranges from 1.9 to 3.8).
• Better bioavailability than unfractionated heparin; subcutaneous administration.
• Less platelet activation and sensitization than unfractionated heparin.
• Excreted by the kidneys necessitating dose adjustment in the presence of renal impairment.
Perioperative considerations:
• Partial thromboplastin time is insensitive to therapeutic doses.
• Measuring antifactor Xa activity should be considered.
• Protamine may reverse 60% of the effect of LMWH.
• In the presence of bleeding, 1 mg protamine can be given for each 100 antifactor Xa units if LMWH was given within 8 hours.
• Discontinue enoxaparin 12 to 24 hours before surgery.
Drugs: bivalirudin, lepirudin, argatroban, and dabigatran. Mechanism of action:
• Direct thrombin inhibitors blocking thrombin's ability to convert fibrinogen to fibrin, activate coagulation factors XI, X, and XII, and platelets. • Bivalirudin is a 20 -amino acid synthetic peptide with a half-life of 25 minutes (determined by proteolysis and renal clearance).
• No direct antagonist; thus, continued use increases the risk for perioperative bleeding.
• Bivalirudin is the most frequently used direct thrombin inhibitor.
• The short half-life of bivalirudin may allow for clearance of the drug in all patients except for those with renal dysfunction. • Bivalirudin is cleared by proteolysis and kidneys;
half-life approximately 25 minutes.
• Dabigatran is an orally active direct thrombin inhibitor.
• Bivalirudin should be stopped Ͼ3 hours before surgery.
• Argatroban should be stopped 4 hours before surgery.
• Lepirudin should be stopped 10 hours before surgery.
Drug: fondaparinux. Mechanism of action:
• Synthetic pentasaccharide inhibits activated factor X (factor Xa inhibitor). • Dose-independent clearance and long half-life more predictable than direct thrombin inhibitors.
• Fixed dose and subcutaneous administration.
• No effect on thrombin that is already formed that may contribute catheter thrombus during percutaneous coronary intervention.
• Not reversed with protamine.
• Major perioperative bleeding can occur, but the risk is lower than with enoxaparin.
• Discontinue fondaparinux 24 hours before CABG surgery.
